A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
about
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysisSNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerCIViC databaseA 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkersA let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabHippo pathway mediates resistance to cytotoxic drugs.Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.MicroRNA-mediated regulation of KRAS in cancerTargeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayMiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.Oncogenes associated with drug resistance in ovarian cancer.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes.The role of microRNAs in cancer susceptibility.KRAS polymorphisms are associated with survival of CRC in Chinese population.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility.A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.In silico analysis of miRNA-mediated gene regulation in OCA and OA genes.Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.
P2860
Q26827474-136E7FC1-C4DB-4C7D-B736-A15EC603176CQ26829794-3254F0E5-AC3F-4328-AFEF-FA31EF13D2BAQ27024235-2F70AE5E-4C0C-40DF-A735-D375D018A7BCQ27612411-AD38FFAB-E33D-4139-A471-B0630E031EE8Q27853046-B322C628-1DE8-4839-870F-C4B79B823783Q28729202-DED75EF0-889F-43F9-AC10-A2DD37A69645Q30374367-9CF1D7E3-CE3E-4EF2-8E41-7F19E84347A3Q33640984-D0EA4D70-5E94-4C3F-9C69-DF2708E046B2Q34138308-1901D1E9-9FC3-466F-915C-434D50974904Q34483581-FABBB44D-7A78-452E-B2C7-0A2E24CCE41BQ34555337-364DE2FB-F841-45AC-AA0B-6E62703420B9Q34669870-51003EBD-F2BD-4DA3-BA7D-CAEA7BB3B60BQ34678120-B070E4DF-8B8F-4C81-92D8-3A28A3D5E8DAQ35079572-35781571-D949-4C2C-8348-F114D97500B7Q35147597-5DEBE281-AB69-4A42-955E-917EF6B0DC8CQ36187913-4A656525-B8DE-4452-BFFE-F5FC130A73B5Q36199823-5DE429C8-5C5D-4AA8-BD5F-D45085D1E531Q36286844-946FF189-B069-4ABB-84F0-B56ABB9B4DDDQ36287562-1A46AFEC-7F9F-4673-9E0A-B8A5BCEBB3CFQ37237962-3486C185-B0EC-4B5D-8C08-C0D35EA5EC02Q37420213-62B1A2B3-5A63-4CD1-8782-4AA98E544285Q37577068-4AAF5763-76B3-4896-B4D6-C676FB2028E0Q37604560-C5909D4A-7A8B-4C0C-A5CA-EB1EFA87191CQ37619736-BAEBDD02-93AF-4E8B-952A-DAAE68F72F5BQ38226577-C7F069E5-E603-4931-8733-5A8C817787D9Q38258014-ABBD9B93-CBCA-4ECF-9112-7962EEEDD7F9Q38383212-40EB2EFE-8EC7-4FEE-B6D8-2DE48CE9C183Q39053707-66D09F9F-F17D-40EE-8AA1-9B68FBF82D40Q39214172-CA6645F1-F8EF-411C-9D9A-F5CB043FC8A4Q39558389-108F3E1C-CE68-49D4-8D72-DF71BA3C11DEQ41170152-7E173739-94A0-40B1-9138-B9E29F187891Q41949668-BA5EE129-1BE5-4602-9DB8-6AC11A8A7111Q47111063-FED5F57C-FD81-4950-8A8F-3DF50938A2D8Q47657039-34102C50-88F2-4C61-AAAB-8BEE2BDB15CEQ50943511-C30E8076-565A-4751-9898-42E1F7381A46Q51064559-880AD68E-FA96-485B-9CF4-2D49C018CF34Q54245253-DBE0D8A6-2BC8-4840-B55B-BA65C71D0DD1
P2860
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@ast
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@en
A KRAS variant is a biomarker ...... for therapy in ovarian cancer.
@nl
type
label
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@ast
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@en
A KRAS variant is a biomarker ...... for therapy in ovarian cancer.
@nl
altLabel
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@en
prefLabel
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@ast
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@en
A KRAS variant is a biomarker ...... for therapy in ovarian cancer.
@nl
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
A KRAS variant is a biomarker ...... for therapy in ovarian cancer
@en
P2093
A D Santin
D Katsaros
D Zelterman
E Bignotti
E S Ratner
J B Weidhaas
P2860
P2888
P304
P3181
P356
10.1038/ONC.2011.539
P407
P577
2012-10-18T00:00:00Z
P5875
P6179
1000308252